Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:businessModel |
gptkb:public_company
|
| gptkbp:CEO |
Gabriel Baertschi
|
| gptkbp:country |
gptkb:Germany
|
| gptkbp:focusArea |
peripheral neuropathy
chronic pain specialty pharmaceuticals inflammatory pain |
| gptkbp:founded |
1946
|
| gptkbp:founder |
Hermann Wirtz
|
| gptkbp:headquarters_location |
gptkb:Aachen
|
| https://www.w3.org/2000/01/rdf-schema#label |
Grünenthal GmbH
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:legalForm |
gptkb:company
|
| gptkbp:notableEvent |
thalidomide scandal
|
| gptkbp:notableProduct |
gptkb:Thalidomide
|
| gptkbp:numberOfEmployees |
~4,500
|
| gptkbp:operatesIn |
gptkb:Europe
gptkb:Latin_America gptkb:United_States gptkb:Asia-Pacific |
| gptkbp:parentCompany |
gptkb:Wirtz_family
|
| gptkbp:revenue |
~€1.7 billion (2022)
|
| gptkbp:specializesIn |
pain management
innovative medicines |
| gptkbp:website |
https://www.grunenthal.com/
|
| gptkbp:bfsParent |
gptkb:Tapentadol
gptkb:Tramadol gptkb:tramadol |
| gptkbp:bfsLayer |
7
|